Clinical Trials Logo

Clinical Trial Summary

This will be an open label, multi-center study of up to 77 patients with CML in chronic, accelerated or blast phase who have developed resistance to or have failed previous treatment with Gleevec (imatinib mesylate). Because these patients may still be sensitive to Gleevec, adding Homoharringtonine may restore a response to Gleevec or the combined treatment may promote a better response than using Gleevec alone.


Clinical Trial Description

Every 4 weeks, the study medicine Homoharringtonine will be given by vein daily for 5 days along with continuing daily doses of the approved medicine Gleevec taken by mouth. The safety and effectiveness of this combined treatment in CML patients will be studied. Patients who do not achieve a meaningful hematologic or cytogenetic response after 4 cycles or less will be discontinued. Otherwise, patients may continue additional cycles of this combined treatment for a maximum of 12 cycles. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00114959
Study type Interventional
Source Teva Pharmaceutical Industries
Contact
Status Terminated
Phase Phase 2
Start date October 2005
Completion date March 2009

See also
  Status Clinical Trial Phase
Completed NCT00482703 - A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia Phase 1/Phase 2
Terminated NCT02086487 - Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy Phase 4
Recruiting NCT00445822 - Registration of Children With CML and Treatment With Imatinib N/A
Completed NCT00478985 - Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia N/A
Terminated NCT02543749 - DC Vaccination in CML Phase 1/Phase 2
Terminated NCT00210119 - Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response Phase 2
Completed NCT02222272 - Effect of 2nd Gen TKI in CML
Completed NCT01660607 - Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell Phase 1/Phase 2
Completed NCT02890784 - Dasatinib Holiday for Improved Tolerability Phase 3
Completed NCT00481247 - A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML Phase 3